Skip to main content

Table 4 Adverse events by treatment group

From: A randomized, placebo-controlled trial of d-cycloserine for the enhancement of social skills training in autism spectrum disorders

  Number (%) of patients reporting  
Adverse Event DCS (N=34) Placebo (N=33) p value
Any Adverse Event 32 (94.1) 28 (84.8) 0.26
Headache (including sinus headache) 9 (26.5) 7 (21.2) 0.80
Nasal congestion or Cold 6 (17.6) 8 (24.2) 0.79
Cough 7 (20.6) 7 (21.2 0.99
Vomiting 6 (17.6) 2 (6.1) 0.29
Aggression 2 (5.9) 5 (15.2) 0.45
Increased motor activity 1 (2.9) 5 (15.2) 0.22
Interrupted sleep/ other sleep problems 3 (8.8) 5 (15.2) 0.73
Irritability (including agitation) 16 (47.1) 15 (45.5) 0.99
Restlessness/Agitation 4 (11.8) 3 (9.1) 0.99
Sadness 5 (14.7) 3 (9.1) 0.73
Sedation/Drowsiness 2 (5.9) 6 (18.2) 0.29
Not otherwise listed 10 (29.4) 12 (36.4) 0.83
Any Serious Adverse Event 0 1 (3.0) 0.99